Right versus left transthoracic approach for lymph node-negative esophageal squamous cell carcinoma by unknown
RESEARCH ARTICLE Open Access
Right versus left transthoracic approach for
lymph node-negative esophageal
squamous cell carcinoma
Qilong Ma†, Wengao Liu†, Hao Long, Tiehua Rong, Lanjun Zhang, Yongbin Lin* and Guowei Ma*
Abstract
Background: To compare the right and left transthoracic approach on the post-operative survival of patients with
lymph node-negative esophageal squamous cell carcinoma.
Methods: Six hundred and ninety-five ESCC patients who underwent esophagectomy between 1990 and 2005 were
retrospectively enrolled in the present study and were confirmed by histology to be of no lymph node metastasis. Those
who had received neoadjuvant chemotherapy or radiotherapy were excluded from the study. Patients were divided into
two groups, the left (n= 545) and right (n = 150) transthoracic groups. The follow-up duration ranged from 1 to 20 years
with a mean of 7 years. Kaplan–Meier and univariate and multivariate Cox proportional hazards were used for analysis.
Results: 3- and 5-year CSS rates were 62.0 % and 44.0 % in the left group, while the corresponding figures in the right
group were 56.0 % and 40.0 %(P < 0.05). The overall survival for the two groups was significantly different (P = 0.045).
Survival analyses were stratified by stages, which found that the favorable survival advantage was not present. When
the survival curves were stratified by tumor locations, a significant difference was not revealed. Surgical approaches
were regarded as one of the prognostic factors in the univariate analysis (P = 0.019). However, this significance could
not be confirmed in multivariate Cox regression analysis (P = 0.193).
Conclusions: The left transthoracic approach is superior in some aspects to the right transthoracic approach regarding
surgical and oncological outcomes in the treatment of lymph node negative ESCC.
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Background
Esophageal cancer (EC) is the eighth most common can-
cer and the sixth leading causes of cancer death world-
wide [1]. The incidence of esophageal cancer, especially
adenocarcinoma, has been on the increase in western
countries [2]. In China, squamous cell carcinoma is the
commonest histological subtype and accounts for over
95 % of the cases [3, 4].
Surgery is the single most effective treatment with
curative intent for esophageal carcinoma [5]. The com-
monest open surgical approaches include transthoracic
and transhiatal esophageal resection. The transthoracic
esophageal resection includes Ivor Lewis (laparotomy
and right thoracotomy), McKeown (right thoracotomy,
laparotomy, and neck incision) and left transthoracic
esophagectomy [6, 7]. We categorized these surgical
approaches as left and right transthoracic approaches in
our study.
A review of the Medicare database of the United States
[8] showed that the mortality rates following esophagec-
tomy ranged from 3.2 % to 6.1 %, and the complication
rates varied from 30 % and 80%with an average of 50 %
[9]. However, the right transthoracic esophagectomy is
preferred to that of the left especially in the western
society because it provides excellent surgical exposure to
the esophagus and regional lymph nodes. Despite this, the
left transthoracic technique still serves as an effective
alternative and is being advocated by many surgeons.
Whether or not there is a difference regarding oncological
outcome between the two approaches is not conclusive.
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Therefore, we well designed this study to compare thor-
oughly the clinical outcomes between the two groups for
lymph node-negative esophageal squamous cell carcinoma
(ESCC).
Methods
This retrospective study was performed by utilizing a
database established at the Sun Yat-sen University Cancer
Center, Guangzhou, China. We enrolled 695 ESCC pa-
tients who underwent esophagectomy in the Department
of Thoracic Surgery between 1990 and 2005 and were
confirmed by histology to be of no lymph node metastasis.
Those who had received neoadjuvant chemotherapy or
radiotherapy were excluded from the study. Patients were
divided into two groups, namely, the left (n = 545) and
right (n = 150) transthoracic groups. The follow-up dur-
ation ranged from 1 to 20 years, with a mean of 7 years.
This study was approved by the Ethics Committee of Sun
Yat-sen University Cancer Center.
The demographic data, surgical and oncological out-
come were obtained from the established database. Baseline
factors included sex, age, smoking history, alcohol con-
sumption history, preoperative hemoglobin level, surgical
duration, anastomosis method, tumor size, location, stage,
and grade. Cancer staging was based on the American Joint
Committee on Cancer (AJCC) staging manual (7th Edition)
[10]. Because all the surgeries were completed before the
publication of AJCC staging manual (7th Edition), it was
challenging to verify the exact tumor locations according to
the new criteria suggested by this version of staging man-
ual. Fortunately, the distances from the superior incisor to
esophageal lesions were well measured and recorded since
every patient received gastroscopy routinely, and there fig-
ures could be used to estimate the tumor locations. In our
study, tumors 15–20 cm distal to the superior incisor were
considered as cervical location, while those 20–25 cm,
25–30 cm, and 30–40 cm distal to the incisor were con-
sidered as upper, middle , and lower thoracic locations,
respectively. Survival time was defined as the time from
surgery to death. To ensure that deaths were exclusively
cancer-related, the patients who either died from other
causes or were still alive at last follow-up were censored.
All the data were analyzed using SPSS Statistics Software
(version 16.0, IBM SPSS, Inc.). The two-tailed Kruskal-
Wallis H test was used to obtain P values. The 3-year and
5-year cancer-specific survival (CSS) rates were obtained
and compared by Life Table Analysis. Survival curves were
generated, and the log rank test was used to determine the
statistical significance of the difference between the two
groups. Stratification analysis was applied to investigate
further the influence of surgical approaches on ESCC of
different stages and locations. P value of less than 0.05 was
considered to be statistically significant.
The left thoracic approach
The patient was placed in the right lateral decubitus
position. A traditional posterolateral incision was made
along the sixth intercostal space in the left hemithorax.
Mediastinal regional lymph nodes were resected in en
bloc fashion with anatomical dissection of the esopha-
gus. The gastric conduit was then harvested via trans-
diaphragmatic approach along with abdominal lymph
node clearance. Gastro-esophageal anastomoses were
constructed in the thorax of 518 (95.0 %) patients and
on the neck of27 (5.0 %) patients.
The right thoracic approach
Firstly, the patient was placed in left lateral decubitus pos-
ition. A standard right posterolateral thoracotomy was
placed along the fifth intercostal space in the right hemi-
thorax. The esophagus along with the regional lymph nodes
in the mediastinal region was removed. Then, the patient
was re-positioned in a supine position. A second upper
midline laparotomy was performed from the umbilicus to
the xyphoid. With preservation of the right gastroeploic ar-
tery, the gastric conduit was harvested along with regional
lymph nodes clearance in the abdominal region. After a
third incision had been made extending along the sterno-
cleidomastoid muscle 6 cm cephalad from the sternal notch
through the platysma, the stomach was then drawn up to
the neck through the chest. Finally, gastro-esophageal anas-
tomoses were constructed in the left neck of 134 (89.3 %)
patients. For the remaining 16 (10.7 %) patients who
received Ivor-Lewis approach, their gastro-esophageal anas-
tomoses were created in the right pleural cavity.
Results
Patient and surgical characteristics
Six hundred and ninety-five ESCC patients were enrolled in
this study, of which 545 (78.4 %) and 150 (21.6 %) patients
underwent the left and right transthoracic approaches, re-
spectively. 70.8 % of the patients (n = 492) were male while
29.2 % (n = 203) were female. Mean age was 55.7 years in
the left group and 56.9 years in the right group (P = 0.192).
In the left group, most patients’ (74.3 %, n = 405) lesions lo-
cated at the middle third of the esophagus, followed by tu-
mors in the lower third of the esophagus (22.9 %, n = 125);
whilst most patients’ lesions in the right group sat at the
middle third of the esophagus (53.3 %, n = 80), followed by
tumors in the upper third of the esophagus (42.0 %, n = 63,
overall P < 0.001). Baseline characteristics of our cohort are
summarized in Table 1. Operation durations were signifi-
cantly different between the left and right transthoracic ap-
proaches with the mean time of 189 and 270 min
respectively (P < 0.001). Greater intraoperative blood loss
was observed in the right transthoracic group compared to
the left group (P < 0.001). The incidence of postopera-
tive complications was significantly higher in the
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former (26.7 % vs. 13.4 %, P < 0.001). In particular,
higher chance of anastomotic leak (P < 0.001), incision
infection (P < 0.001), and respiratory complications (P =
0.044) in the right transthoracic group were demonstrated
in our study (Table 2). There were no significant differ-
ences regarding gender, age, smoking history, alcohol con-
sumption history, preoperative hemoglobin level, tumor
location, size, stage, and grade between the two groups.
Survival analysis
3- and 5-year CSS rates were 62.0 % and 44.0 % in the
left group, while the corresponding figures in the right
group were 56.0 % and 40.0 % respectively (P < 0.05).
Similarly, the specific cancer survival for the two groups
was significantly different (P = 0.045) (Fig. 1). Survival
analyses were stratified further in terms of tumor stages,
which found that the favorable survival advantage was not
particularly present (Fig. 2). When the survival curves
were stratified by tumor locations, a significant difference
was not revealed between the two groups (Fig. 3). Surgical
approaches were regarded as one of the prognostic factors
in the univariate analysis (P = 0.019). However, this signifi-
cance could not be confirmed in multivariate Cox regres-
sion analysis (P = 0.193) (Tables 3 and 4).
Table 1 Baseline characteristics of patients grouped by surgical
approach
Characteristic Left transthoracic
approach (n = 545)
Right transthoracic
approach (n = 150)
P
Sex 0.995
Male 386 (70.6 %) 106 (70.7 %)
Female 159 (29.4 %) 44 (29.3 %)
Average age 55.66 ± 9.85 56.91 ± 8.42 0.192
Smoking history 324 (59.4 %) 89 (59.3 %) 0.980
Drinking history 109 (20.0 %) 28 (18.7 %) 0.716
Preoperative
hemoglobin
134.33 ± 18.65 132.49 ± 17.38 0.222
Preoperative FEV1 2.42 ± 3.50 2.37 ± 0.70 0.086
Duration of surgery 189.24 ± 50.41 270.83 ± 68.38 <0.001
Blood loss during
surgery




Cervical 27(5.0 %) 134 (89.3 %)
Intrathoracic 518 (95.0 %) 16 (10.7 %)
Length of tumor 4.81 ± 1.96 4.67 ± 1.79 0.288
Pathological stage 0.336
Ia 48 (8.8 %) 11(7.3 %)
Ib 258 (47.3 %) 67 (44.7 %)
IIa 239 (43.9 %) 72 (48.0 %)
Location of tumor <0.001
Upper third 15 (2.8 %) 63 (42.0 %)
Middle third 405 (74.3 %) 80 (53.3 %)
Lower third 125 (22.9 %) 7 (4.7 %)
Method of anastomosis 0.006
Manual 50 (9.2 %) 124 (82.7 %)




High 213 (39.1 %) 44 (29.3 %)
Middle 219 (40.1 %) 74 (49.3 %)
Low 113 (20.7 %) 32 (21.3 %)
Number of resected LNsa 9.18 ± 5.48 9.61 ± 8.02 0.171
Postoperative
complications
73 (13.4 %) 40 (26.7 %) <0.001
FEV1 forced expiratory volume in 1 second
LNs lymph nodes
Table 2 Incidence of postoperative complications in ESCC






Anastomotic fistula 10 (1.8) 18 (12.0) <0.001
Anastomotic stenosis 14 (2.6) 7 (4.7) 0.155
Incision site infection 2 (0.4) 8 (5.3) <0.001
Injury of recurrent
laryngeal nerves
4 (0.7) 4 (2.7) 0.075
Chylothorax 3 (0.6) 2 (1.3) 0.303
Pneumothorax 12 (2.2) 3 (2.0) 0.574
Complication of
respiratory tract
7 (1.3) 6 (4.0) 0.044
Complication of
cardiovascular system
5 (0.9) 2 (1.3) 0.477
Fig. 1 Overall survival curves. The cancer specific survival for the two
groups was significant different (P = 0.045)
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Fig. 2 Cancer-specific survival curves stratified by tumor stage. Survival
analyses were further stratified in terms of tumor stages, which found
that the favorable survival advantage was not particularly present
Fig. 3 Cancer-specific survival curves stratified by tumor location.
When the survival curves were stratified by tumor locations, a
significant difference was not revealed between the two groups
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Discussion
Esophageal cancer is one of the leading causes of
cancer-related mortality worldwide [1]. The prevalence
of esophageal cancer, especially adenocarcinoma, has in-
creased in western countries [2]. In China, the squamous
cell carcinoma is the most common histological subtype
and accounts for over 95 % of the cases [1].
Radical surgery is still the single most important mo-
dality in the multidisciplinary treatment of esophageal
cancer. However, there are still many controversies sur-
rounding the surgical resection of esophageal cancer
way. No matter which kind of operation method chosen,
the most important factoris that the surgical techniques
chosen should have the following features: simple oper-
ation process, small trauma to the patient, fewer compli-
cations after surgery, removal of the tumor or the lymph
nodes to the greatest extent. Some surgeons advocated
the transhiatal esophagectomy for its lower morbidity
and mortality with an inadequate lymphadenectomy.
Previous studies showed that the optimum extent of
lymph node resection is significantly associated with
long-term survival after surgery, the group after trans-
thoracic esophageal resection in cleaning the number of
lymph nodes is greater than the transhiatal esophageal
resection group [11–13]. Choice of surgical techniques,
like three-incision transthoracic esophagectomy with
three-field lymph node dissection would depend on the
patient’s condition and the surgeon’s individual prefer-
ence [14]. The surgical approaches include left and right
transthoracic approaches brought into the current study
are the most common used in China. For tumors located
in the middle or lower thoracic esophagus, some sur-
geons advocated left transthoracic esophagectomy rather
than the right one, the left approach has many advan-
tages in the treatment of middle or lower third esopha-
geal carcinoma, especially with regard to the lower
incidence of postoperative complications and shorter
hospital stay [15, 16]. There were also some researches
demonstrate that the Ivor-Lewis procedure can be per-
formed with lower rates of postoperative complications
and more lymph node retrieval. Then we want to find
the clinical outcomes for lymph node-negative esopha-
geal squamous cell carcinoma (ESCC) [17].
Postoperative mortality for esophageal carcinoma, as
reported in the literature, ranges from 0 % to 10 % Septi-
cemia, secondary to anastomotic leak and pneumonia
among all the relevant complications, are the primary
causes of death. The average morbidity rate was reported
to be 40.3 %, varying from 26.1 % to 80.4 %. Overall 5-
year CSS rate was revealed to be between 40 % and 50 %
[18]. On the other hand, the overall incidence of tumor
recurrence is approximately 14 % [19–22]. We only en-
rolled the ESCC patients without lymph node metastasis
in this comparison study, as a more homogeneous popu-
lation with less confusing parameters would make our
conclusion more specific and reliable.
Our study found that postoperative CSS rate was bet-
ter in the left than the right transthoracic group. When
the data were stratified, the survival advantage favoring
the left transthoracic approach was only present for
stage Ib tumors and tumors in the middle third of the
esophagus. These survival differences may have resulted
from several factors.
Firstly, related anatomies and surgical exposure are
dramatically different between the two approaches. Ad-
mittedly, the right transthoracic approach could provide
excellent surgical exposure to the esophagus and its
drainage lymphatic areas. However, with the left thora-
cotomy, most of the thoracic field’s lymph nodes could
also be accessed; however, there might be some interfer-
ence from the aortic arch. The manipulation of abdom-
inal field is slightly challenging but still accessible after
the diaphragm is widely opened. This technique, if used
correctly, could offer satisfactory surgical exposure for
sufficient tumor and lymph node resection in a single in-
cision. Some researchers found that lymph node metas-
tasis was more common in the patients with tumors in
the middle or lower segments of the esophagus, and the
Table 3 Possible prognostic factors and relative risks
Possible prognostic factors P Hazard ratio 95 % Confidence
interval
Age 0.003 1.108 1.006–1.030
Smoking history <0.001 1.601 1.273–2.014
Drinking history <0.001 1.687 1.321–2.155




Tumor staging <0.001 1.470 1.231–1.755
Tumor location 0.249 0.887 0.724–1.087
Operation approach 0.019 1.101 1.016–1.193
Location of anastomosis 0.081 0.808 0.635–1.026
Method of anastomosis 0.731 0.955 0.733–1.244
Complications 0.132 0.812 0.619–1.065
Table 4 Survival differences after multivariate Cox proportional
hazard regression analysis
Item P by Cox
regression
Hazard ratio 95 % Confidence
interval
Age 0.011 1.016 1.004–1.028
Smoking history 0.028 1.314 1.030–1.677
Drinking history 0.001 1.556 1.201–2.015
Duration of surgery 0.207 1.001 0.999–1.003
Tumor staging 0.000 1.441 1.205–1.723
Operation approach 0.193 1.064 0.969–1.168
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metastases were disseminated all the way from the cer-
vical to abdominal areas [23]. Therefore, adequate ex-
posure and resection are critical for ESCC patients.
Secondly, surgical time was significantly different between
the left and right transthoracic approaches, with the mean
time of 189 and 271 min, respectively (P < 0.001). It could
be easily understood that the need for re-positioning the
patients and two or three incisions would naturally make
the right transthoracic surgery longer in the operation time.
The drawback of prolonged surgical duration, if any, would
mean the exposure of patients to higher anesthesia-related
risks.
Moreover, the current study showed that postoperative
complication rates were higher in the right group than
those in the left group (26.7 % vs. 13.4 %, P < 0.001). We
found that the incidence of anastomotic leak, incision
infection, and respiratory complications were more com-
mon in the right transthoracic group. More incisions in
the right transthoracic approach would result in more
severe post-operative pain and analgesia that is more in-
tensive, which in turn would increase the chances of in-
fection. Anastomosis is more frequently constructed in
the upper thorax or the neck in the right transthoracic
approach, which may contribute to a higher tension on
the anastomosis. However, the occurrence of complica-
tions is multi-factorial, like acute inflammatory reaction
and anesthetic factors; therefore, further research needs
to be carried out before we can substantiate our claim.
According to the outcomes of univariate and multi-
variate Cox regression analyses, the surgical approach is
one of the factors that significantly influences prognosis.
The strengths and limitations of our study should be
considered while interpreting these results. The strengths
include a large sample of consecutive patients from a well-
maintained database and an efficient record system con-
taining abundant tumor information such as tumor grade
and stage. Furthermore, we conducted detailed stratified
analyses regarding tumor stages and locations in our
study, and multivariate analysis was used to explore po-
tential impact factors.
A retrospective study, even when well designed, would
inevitably have limitations. Our study included only
patients with ESCC and excluded those with esophageal
adenocarcinoma. This indicates that our conclusion would
not be applicable in the regions where the esophageal
adenocarcinoma is prevalent. Because all the surgeries
were completed before the publication of AJCC staging
manual (7th Edition), it was challenging to verify the exact
tumor locations according to the new criteria suggested
by this version of staging manual. We could only roughly
estimate the tumor locations by categorizing the distances
from the superior incisor to esophageal lesions recorded
in gastroscopy, without given consideration to some fac-
tors like patient’s height.
Conclusions
In conclusion, after a careful comparison, we found that
the left transthoracic approach is not in anyway inferior to
the right transthoracic. Our study revealed that it is super-
ior, in some aspects, to the right transthoracic approach
regarding surgical and oncological outcomes in the treat-
ment of lymph node negative ESCC.
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